Intervention

Androgen Deprivation Therapy

ClinicalTrials.gov intervention label

Clinical trials14

Recruiting5

Common conditions12

Lead sponsors shown13

Clinical trials

14 shown

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate CancerNCT05726292 · 2025-01-06

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.NCT06274047 · 2024-09-10

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate CancerNCT06392295 · 2024-07-03

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of LifeNCT06171269 · 2024-01-05

Pembro With Radiation With or Without OlaparibNCT05568550 · 2023-07-27

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate CancerNCT04465500 · 2025-01-30

ACTIVE_NOT_RECRUITING

Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.NCT06500247 · 2024-07-31

NOT_YET_RECRUITING

ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcerNCT05567770 · 2023-12-01

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate CancerNCT04737109 · 2021-07-13

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.NCT07428642 · 2020-09-01

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed TumorsNCT04126070 · 2020-05-11

ACTIVE_NOT_RECRUITING

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation TherapyNCT03543189 · 2018-10-03

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate CancerNCT01957436 · 2013-11-13

ACTIVE_NOT_RECRUITING

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local TherapyNCT00776594 · 2008-10-01

Common conditions

Prostate Cancer9 Prostate Adenocarcinoma4 Hormone Sensitive Prostate Cancer2 Androgen Axis Suppression1 Castrate Resistant Prostate Cancer1 Metastasis Prostate Adenocarcinoma1 Metastatic Hormone-Sensitive Prostate Cancer1 Metastatic Prostate Cancer1 Prostate Cancer Metastatic1 Prostate Disease1 Prostatectomy1 The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer1

Leading sponsors

University of Chicago2 Dana-Farber Cancer Institute1 David VanderWeele1 First Affiliated Hospital of Wenzhou Medical University1 H. Lee Moffitt Cancer Center and Research Institute1 M.D. Anderson Cancer Center1 Qilu Hospital of Shandong University1 UNICANCER1 University of Miami1 University of Virginia1 Weill Medical College of Cornell University1 Xiao X. Wei, MD1 Zin W Myint1

Trial status mix

RECRUITING5

ACTIVE_NOT_RECRUITING3

COMPLETED3

NOT_YET_RECRUITING1

TERMINATED1

WITHDRAWN1

Phase mix

PHASE29

PHASE13

PHASE32

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.